AN MRL/MPJ-LPR/LPR SUBSTRAIN WITH A LIMITED EXPANSION OF LPR DOUBLE-NEGATIVE T-CELLS AND A REDUCED AUTOIMMUNE SYNDROME

被引:32
作者
FOSSATI, L
TAKAHASHI, S
MERINO, R
IWAMOTO, M
AUBRY, JP
NOSE, M
SPACH, C
MOTTA, R
IZUI, S
机构
[1] UNIV GENEVA,CTR MED,DEPT PATHOL,CH-1211 GENEVA 4,SWITZERLAND
[2] GLAXO INST MOLEC BIOL,GENEVA,SWITZERLAND
[3] TOHOKU UNIV,SCH MED,DEPT PATHOL,SENDAI,MIYAGI 980,JAPAN
[4] CTR MARCEL DELEPINE,IMMUNOGENET LAB,CNRS,ORLEANS,FRANCE
关键词
AUTOIMMUNITY; LYMPHOPROLIFERATION; MUTANT MOUSE; SYSTEMIC LUPUS ERYTHEMATOSUS;
D O I
10.1093/intimm/5.5.525
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The autosomal recessive mutant gene, Ipr, has been shown to accelerate the progression of lupus-like autoimmune disease, which is associated with a massive expansion of a unique CD4-CD8- double-negative T cell subset, in MRL/MpJ mice. Here we report a substrain of MRL/MpJ-Ipr/Ipr (MRL-Ipr) mice which live almost twice as long with delayed development of glomerulonephritis, compared with conventional MRL-Ipr mice. This substrain, termed MRL-Ipr.II (II for long-lived), develops generalized lymphadenopathy characteristically seen in MRL-Ipr mice. However, the expansion of a double negative Ipr T cell subset is markedly limited with a mean value of 15% in their lymph nodes compared to about 70% in conventional MRL-Ipr mice. Overall production of autoantibodies, such as anti-DNA and rheumatoid factors, does not significantly differ between the two MRL-Ipr mice. However, serum levels of cryoglobulins, whose major component is IgG3, are markedly diminished in MRL-Ipr.II mice with a parallel decrease in IgG3. Since MRL-Ipr.II mice still carry the Ipr mutation, as documented by the presence of defects in the Fas antigen, a possible new mutation in this substrain may play a significant role in the pathogenesis of lupus-like autoimmune syndrome.
引用
收藏
页码:525 / 532
页数:8
相关论文
共 39 条
[1]  
ABDELMOULA M, 1989, J IMMUNOL, V143, P526
[2]   SPONTANEOUS MURINE LUPUS-LIKE SYNDROMES - CLINICAL AND IMMUNOPATHOLOGICAL MANIFESTATIONS IN SEVERAL STRAINS [J].
ANDREWS, BS ;
EISENBERG, RA ;
THEOFILOPOULOS, AN ;
IZUI, S ;
WILSON, CB ;
MCCONAHEY, PJ ;
MURPHY, ED ;
ROTHS, JB ;
DIXON, FJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1978, 148 (05) :1198-1215
[3]  
ASANO T, 1988, CLIN EXP IMMUNOL, V74, P36
[4]   SELECTIVE PATHOGENICITY OF MURINE RHEUMATOID FACTORS OF THE CRYOPRECIPITABLE IGG3 SUBCLASS [J].
BERNEY, T ;
FULPIUS, T ;
SHIBATA, T ;
REININGER, L ;
VANSNICK, J ;
SHAN, H ;
WEIGERT, M ;
MARSHAKROTHSTEIN, A ;
IZUI, S .
INTERNATIONAL IMMUNOLOGY, 1992, 4 (01) :93-99
[5]  
BERNEY T, 1991, J IMMUNOL, V147, P3331
[6]   ELEVATED PRODUCTION OF INTERFERON-GAMMA AND INTERLEUKIN-4 BY MATURE T-CELLS FROM AUTOIMMUNE LPR MICE CORRELATES WITH PGP-1 (CD44) EXPRESSION [J].
BUDD, RC ;
SCHUMACHER, JH ;
WINSLOW, G ;
MOSMANN, TR .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1991, 21 (04) :1081-1084
[7]  
CERNY A, 1989, CLIN EXP IMMUNOL, V77, P124
[8]   GAMMA-INTERFERON ENHANCES MACROPHAGE TRANSCRIPTION OF THE TUMOR-NECROSIS-FACTOR CACHECTIN, INTERLEUKIN-1, AND UROKINASE GENES, WHICH ARE CONTROLLED BY SHORT-LIVED REPRESSORS [J].
COLLART, MA ;
BELIN, D ;
VASSALLI, JD ;
DEKOSSODO, S ;
VASSALLI, P .
JOURNAL OF EXPERIMENTAL MEDICINE, 1986, 164 (06) :2113-2118
[9]  
DAVIGNON JL, 1988, J IMMUNOL, V141, P1848
[10]  
DAVIGNON JL, 1985, J IMMUNOL, V135, P2423